[HTML][HTML] Cannabinoids: therapeutic use in clinical practice

C Pagano, G Navarra, L Coppola, G Avilia… - International journal of …, 2022 - mdpi.com
Medical case reports suggest that cannabinoids extracted from Cannabis sativa have
therapeutic effects; however, the therapeutic employment is limited due to the psychotropic …

Cannabinoids and the expanded endocannabinoid system in neurological disorders

L Cristino, T Bisogno, V Di Marzo - Nature Reviews Neurology, 2020 - nature.com
Anecdotal evidence that cannabis preparations have medical benefits together with the
discovery of the psychotropic plant cannabinoid Δ9-tetrahydrocannabinol (THC) initiated …

Medical use of cannabinoids

AI Fraguas-Sánchez, AI Torres-Suárez - Drugs, 2018 - Springer
Cannabinoid receptors, endocannabinoids and the enzymes responsible for their
biosynthesis and degradation constitute the endocannabinoid system. In recent decades …

Direct and indirect pathways of basal ganglia: a critical reappraisal

P Calabresi, B Picconi, A Tozzi, V Ghiglieri… - Nature …, 2014 - nature.com
The basal ganglia are subcortical nuclei controlling voluntary actions and have been
implicated in Parkinson's disease (PD). The prevailing model of basal ganglia function …

Endocannabinoids and endocannabinoid-related mediators: Targets, metabolism and role in neurological disorders

FA Iannotti, V Di Marzo, S Petrosino - Progress in lipid research, 2016 - Elsevier
The endocannabinoid system (ECS) is composed of two G protein-coupled receptors
(GPCRs), the cannabinoid CB1 and CB2 receptors, and the two main endogenous lipid …

[HTML][HTML] The role of lipids in Parkinson's disease

H Xicoy, B Wieringa, GJM Martens - Cells, 2019 - mdpi.com
Parkinson's disease (PD) is a neurodegenerative disease characterized by a progressive
loss of dopaminergic neurons from the nigrostriatal pathway, formation of Lewy bodies, and …

The endocannabinoid system as an emerging target of pharmacotherapy

P Pacher, S Bátkai, G Kunos - Pharmacological reviews, 2006 - ASPET
The recent identification of cannabinoid receptors and their endogenous lipid ligands has
triggered an exponential growth of studies exploring the endocannabinoid system and its …

Endocannabinoid system in neurodegenerative disorders

BS Basavarajappa, M Shivakumar… - Journal of …, 2017 - Wiley Online Library
Most neurodegenerative disorders (NDD s) are characterized by cognitive impairment and
other neurological defects. The definite cause of and pathways underlying the progression …

Targeting the endocannabinoid system: to enhance or reduce?

V Di Marzo - Nature reviews Drug discovery, 2008 - nature.com
As our understanding of the endocannabinoids improves, so does the awareness of their
complexity. During pathological states, the levels of these mediators in tissues change, and …

The pharmacology of L-DOPA-induced dyskinesia in Parkinson's disease

P Huot, TH Johnston, JB Koprich, SH Fox… - Pharmacological …, 2013 - ASPET
l-3, 4-Dihydroxyphenylalanine (l-DOPA) remains the most effective symptomatic treatment of
Parkinson's disease (PD). However, long-term administration of l-DOPA is marred by the …